166 related articles for article (PubMed ID: 15801952)
1. Biology and management of relapsed acute myeloid leukaemia.
Craddock C; Tauro S; Moss P; Grimwade D
Br J Haematol; 2005 Apr; 129(1):18-34. PubMed ID: 15801952
[TBL] [Abstract][Full Text] [Related]
2. Progress and strategies for patients with relapsed and refractory acute myeloid leukemia.
Litzow MR
Curr Opin Hematol; 2007 Mar; 14(2):130-7. PubMed ID: 17255790
[TBL] [Abstract][Full Text] [Related]
3. [Treatment of acute myeloid leukemias in the adult in relapse].
Thomas X; Le QH
Bull Cancer; 2002 Sep; 89(9):795-807. PubMed ID: 12368132
[TBL] [Abstract][Full Text] [Related]
4. Prognostic factors and therapeutic options for relapsed or refractory acute myeloid leukemia.
Ferrara F; Palmieri S; Mele G
Haematologica; 2004 Aug; 89(8):998-1008. PubMed ID: 15339685
[TBL] [Abstract][Full Text] [Related]
5. High-dose melphalan is an effective salvage therapy in acute myeloid leukaemia patients with refractory relapse and relapse after autologous stem cell transplantation.
Bug G; Atta J; Klein SA; Hertenstein B; Bergmann L; Boehrer S; Mousset S; Hoelzer D; Martin H
Ann Hematol; 2005 Oct; 84(11):748-54. PubMed ID: 16001243
[TBL] [Abstract][Full Text] [Related]
6. Disease burden may identify patients more likely to benefit from second allogeneic hematopoietic stem cell transplantation to treat relapsed acute myelogenous leukemia.
Hosing C; Saliba RM; Shahjahan M; Estey EH; Couriel D; Giralt S; Andersson B; Champlin RE; De Lima M
Bone Marrow Transplant; 2005 Jul; 36(2):157-62. PubMed ID: 15937511
[TBL] [Abstract][Full Text] [Related]
7. Outcomes of patients with acute leukaemia who relapsed after reduced-intensity stem cell transplantation from HLA-identical or one antigen-mismatched related donors.
Kobayashi K; Kami M; Murashige N; Kusumi E; Kishi Y; Hamaki T; Hori A; Matsumura T; Yuji K; Masuo S; Mori S; Miyakoshi S; Tanosaki R; Mitamura T; Takaue Y; Taniguchi S;
Br J Haematol; 2005 Jun; 129(6):795-802. PubMed ID: 15953007
[TBL] [Abstract][Full Text] [Related]
8. Allogeneic stem-cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasia.
Tauro S; Craddock C; Peggs K; Begum G; Mahendra P; Cook G; Marsh J; Milligan D; Goldstone A; Hunter A; Khwaja A; Chopra R; Littlewood T; Peniket A; Parker A; Jackson G; Hale G; Cook M; Russell N; Mackinnon S
J Clin Oncol; 2005 Dec; 23(36):9387-93. PubMed ID: 16314618
[TBL] [Abstract][Full Text] [Related]
9. Emerging treatments in acute myeloid leukaemia.
Kell J
Expert Opin Emerg Drugs; 2004 May; 9(1):55-71. PubMed ID: 15155136
[TBL] [Abstract][Full Text] [Related]
10. Treatment of relapsed acute leukemia after allogeneic transplantation: a single center experience.
Arellano ML; Langston A; Winton E; Flowers CR; Waller EK
Biol Blood Marrow Transplant; 2007 Jan; 13(1):116-23. PubMed ID: 17222760
[TBL] [Abstract][Full Text] [Related]
11. Outcome of patients with acute myelogenous leukemia after second salvage therapy.
Giles F; O'Brien S; Cortes J; Verstovsek S; Bueso-Ramos C; Shan J; Pierce S; Garcia-Manero G; Keating M; Kantarjian H
Cancer; 2005 Aug; 104(3):547-54. PubMed ID: 15973664
[TBL] [Abstract][Full Text] [Related]
12. Salvage therapy in Hodgkin's lymphoma.
Mendler JH; Friedberg JW
Oncologist; 2009 Apr; 14(4):425-32. PubMed ID: 19342476
[TBL] [Abstract][Full Text] [Related]
13. Prognostic factors and risk-based therapy in pediatric acute myeloid leukemia.
Meshinchi S; Arceci RJ
Oncologist; 2007 Mar; 12(3):341-55. PubMed ID: 17405900
[TBL] [Abstract][Full Text] [Related]
14. Heterogeneity in the therapeutic approach to relapsed elderly patients with acute myeloid leukaemia: a survey from the Gruppo Italiano Malattie Ematologiche dell' Adulto (GIMEMA) Acute Leukaemia Working Party.
Ferrara F; Fazi P; Venditti A; Pagano L; Amadori S; Mandelli F
Hematol Oncol; 2008 Jun; 26(2):104-7. PubMed ID: 18271064
[TBL] [Abstract][Full Text] [Related]
15. Sequential continuous infusion of fludarabine and cytarabine associated with liposomal daunorubicin (DaunoXome) (FLAD) in primary refractory or relapsed adult acute myeloid leukemia patients.
Camera A; Rinaldi CR; Palmieri S; Cantore N; Mele G; Mettivier V; Miraglia E; Mastrullo L; Grimaldi F; Luciano L; Guerriero A; Rotoli B; Ferrara F
Ann Hematol; 2009 Feb; 88(2):151-8. PubMed ID: 18709502
[TBL] [Abstract][Full Text] [Related]
16. Successful treatment of relapsed AML after allogeneic stem cell transplantation with azacitidine.
Graef T; Kuendgen A; Fenk R; Zohren F; Haas R; Kobbe G
Leuk Res; 2007 Feb; 31(2):257-9. PubMed ID: 16620971
[TBL] [Abstract][Full Text] [Related]
17. Curing childhood acute myeloid leukemia (AML) at the half-way point: promises to keep and miles to go before we sleep.
Woods WG
Pediatr Blood Cancer; 2006 May; 46(5):565-9. PubMed ID: 16261562
[TBL] [Abstract][Full Text] [Related]
18. Autologous stem cell transplantation in the treatment of adults with acute myeloid leukaemia.
Breems DA; Löwenberg B
Br J Haematol; 2005 Sep; 130(6):825-33. PubMed ID: 16156852
[TBL] [Abstract][Full Text] [Related]
19. The role of autologous transplantation for acute myeloid leukemia in first and second remission.
Linker C
Best Pract Res Clin Haematol; 2007 Mar; 20(1):77-84. PubMed ID: 17336257
[TBL] [Abstract][Full Text] [Related]
20. Low-dose total body irradiation-based regimens as a preparative regimen for allogeneic haematopoietic cell transplantation in acute myelogenous leukaemia.
Al-Ali H; Cross M; Lange T; Freund M; Dölken G; Niederwieser D
Curr Opin Oncol; 2009 Jun; 21 Suppl 1():S17-22. PubMed ID: 19561407
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
